

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM S-8  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

**Avalo Therapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other Jurisdiction  
of Incorporation or Organization)

**45-0705648**  
(I.R.S. Employer Identification Number)

**540 Gaither Road, Suite 400**  
**Rockville, Maryland 20850**  
(Address, including zip code, of registrant's principal executive offices)

**Non-Qualified Stock Option Inducement Awards**  
(Full title of the plans)

**Christopher Sullivan, Chief Financial Officer**  
**Avalo Therapeutics, Inc.**  
**540 Gaither Road, Suite 400**  
**Rockville, Maryland 20850**  
**(410) 522-8707**  
(Name, address, including zip code, and telephone number, including area code, of agent for service)

COPIES TO:  
**Andrew J. Gibbons, Esq.**  
**Alexander M. Donaldson, Esq.**  
**Wyrick Robbins Yates & Ponton LLP**  
**4101 Lake Boone Trail, Suite 300**  
**Raleigh, North Carolina 27607**  
**(919) 781-4000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
	(Do not check if smaller reporting company)	Emerging Growth Company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

## EXPLANATORY NOTE

This Registration Statement on Form S-8 covers up to 384,000 shares of Common Stock of Avalo Therapeutics, Inc. (the “Registrant”), issuable upon the exercise of stock options issued as inducement grants to certain of the Registrant’s employees (the “Inducement Grants”). The Inducement Grants were made outside of the Registrant’s Fourth Amended and Restated 2016 Equity Incentive Plan and any other equity plan established by the Registrant.

### PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.

The following documents previously filed by the Registrant with the Commission are incorporated herein by reference:

(a) The Registrant’s [Annual Report on Form 10-K for the fiscal year ended December 31, 2023](#), filed with the Commission on March 29, 2024, pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

(b) The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31 (as amended by Form 10-Q/A), June 30 and September 30, 2024 filed with the Commission on [May 13](#) (and amended on [July 11](#)), [August 12](#) and [November 7, 2024](#), respectively, pursuant to Section 13(a) of the Exchange Act;

(c) The Registrant’s Current Reports on Form 8-K filed pursuant to Section 13(a) of the Exchange Act on [January 31](#), [March 28](#) (as amended by Forms 8-K/A filed on [June 3](#) and [June 24](#)), [May 23](#), [June 24](#) (two filings), [July 9](#), [July 16](#), [July 30](#), [August 14](#), [September 4](#), [September 9](#), and [October 8, 2024](#); and

(d) The description of the Registrant’s common stock contained in [Exhibit 4.16](#) to the Registrant’s Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 29, 2024, including any amendments or reports filed for the purpose of updating such description.

All documents or portions thereof filed, but not furnished, by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof and prior to the filing of a post-effective amendment that indicates that all securities offered under this Registration Statement have been sold or which deregisters all securities then remaining unsold shall be considered incorporated by reference herein and to be a part hereof from the date the documents are filed. In no event, however, will any of the information, including exhibits, that we disclose under Item 2.02 or Item 7.01 of any report on Form 8-K that has been or may be, from time to time, furnished to the Commission, be incorporated by reference into or otherwise become a part of this Registration Statement.

Any statement contained in a document incorporated or considered incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document that also is or is considered incorporated by reference herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be considered, except as so modified or superseded, to constitute a part hereof.

#### Item 6. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to believe his or her conduct was unlawful. In the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person has been adjudged to be liable to the corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the circumstances.

The Registrant's Certificate of Incorporation and Bylaws provide that its directors and officers will be indemnified by the Registrant to the fullest extent authorized by the Delaware General Corporation Law. In addition, the Registrant's Certificate of Incorporation provides, as permitted by Section 102(b)(7) of the Delaware General Corporation Law, that its directors will not be liable for monetary damages to the Registrant for breaches of their fiduciary duty as directors, unless they (i) violated their duty of loyalty to the Registrant or its stockholders, (ii) acted, or failed to act, in good faith, (iii) acted with intentional misconduct, (iv) knowingly or intentionally violated the law, (v) authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or (vi) derived an improper personal benefit from their actions as directors.

The Registrant's Bylaws also permit the Registrant to secure insurance on behalf of any officer, director, employee, or agent for any liability arising out of his or her actions, regardless of whether Delaware General Corporation Law would permit indemnification. The Registrant has purchased a policy of directors' and officers' liability insurance that insures its directors and officers.

In addition, the Registrant has also entered into an indemnification agreement with certain of its directors and officers. The indemnification agreements require the Registrant to indemnify and hold harmless and advance expenses to each indemnitee in respect of acts or omissions occurring prior to the time the indemnitee ceases to be an officer and/or director of the Registrant to the fullest extent permitted by applicable law. The rights provided in the indemnification agreements are in addition to the rights provided in the Registrant's Certificate of Incorporation, Bylaws, and the Delaware General Corporation Law.

#### **Item 8. Exhibits.**

The following exhibits are filed as part of this Registration Statement:

<u>Exhibit No.</u>	<u>Description</u>
4.1	<a href="#"><u>Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1.2 to the Current Report on Form 8-K filed with the Commission on May 17, 2018).</u></a>
4.2	<a href="#"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on August 26, 2021).</u></a>
4.3	<a href="#"><u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on July 7, 2022).</u></a>
4.4	<a href="#"><u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Avalo Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the Commission on December 28, 2023).</u></a>
4.5	<a href="#"><u>Avalo Therapeutics, Inc. Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed with the Commission on March 29, 2024).</u></a>
5.1*	<a href="#"><u>Opinion of Wyrick Robbins Yates &amp; Ponton LLP.</u></a>
23.1*	<a href="#"><u>Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</u></a>
23.2*	<a href="#"><u>Consent of Wyrick Robbins Yates &amp; Ponton LLP (included in Exhibit 5.1)</u></a>
24.1*	<a href="#"><u>Power of Attorney (included on signature page to this Registration Statement on Form S-8).</u></a>
107*	<a href="#"><u>Filing Fee Table.</u></a>

\* Filed herewith.

**[THE NEXT PAGE IS THE SIGNATURE PAGE]**

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on the 7<sup>th</sup> day of November, 2024.

**AVALO THERAPEUTICS, INC.**

By: /s/ Christopher Sullivan  
Christopher Sullivan  
Chief Financial Officer

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Garry A. Neil and Christopher Sullivan, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Capacity	Date
/s/ Garry A. Neil, M.D. <b>Garry A. Neil, M.D.</b>	Chief Executive Officer, Director and Chairman <i>(Principal Executive Officer)</i>	November 7, 2024
/s/ Christopher Sullivan <b>Christopher Sullivan</b>	Chief Financial Officer <i>(Principal Financial and Accounting Officer)</i>	November 7, 2024
/s/ June Almenoff, M.D., Ph.D. <b>June Almenoff, M.D., Ph.D.</b>	Director	November 7, 2024
/s/ Mitchell Chan <b>Mitchell Chan</b>	Director	November 7, 2024
/s/ Jonathan Goldman, M.D. <b>Jonathan Goldman, M.D.</b>	Director	November 7, 2024
/s/ Aaron Kantoff <b>Aaron Kantoff</b>	Director	November 7, 2024
/s/ Gilla Kaplan, Ph.D. <b>Gilla Kaplan, Ph.D.</b>	Director	November 7, 2024
/s/ Samantha Truex <b>Samantha Truex</b>	Director	November 7, 2024

**Calculation of Filing Fee Table**

**Form S-8**  
(Form Type)

**Avalo Therapeutics, Inc.**  
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Share <sup>(4)</sup>	Maximum Aggregate Offering Price <sup>(4)</sup>	Fee Rate	Amount of Registration Fee
Equity	Common Stock, \$0.001 par value per share	Rule 457(h)	234,000 shares <sup>(2)</sup>	\$ 12.65	\$ 2,960,100	\$ 0.0001531	\$ 453
Equity	Common Stock, \$0.001 par value per share	Rule 457(h)	150,000 shares <sup>(3)</sup>	\$ 13.43	\$ 2,014,500	\$ 0.0001531	\$ 308
<b>Total Offering Amounts</b>			384,000 shares		\$ 4,974,600		761
<b>Total Fee Offsets</b>							\$ —
<b>Net Fee Due</b>							<u>\$ 761</u>

- (1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.’s common stock, par value \$0.001 per share (the “Common Stock”), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.
- (2) Represents 234,000 shares of Common Stock issuable under the inducement stock option award pursuant to a stock option agreement entered into with Mittie Doyle on July 15, 2024.
- (3) Represents 150,000 shares of Common Stock issuable under the inducement stock option award pursuant to a stock option agreement entered into with Paul Varki on June 24, 2024.
- (4) Such shares are issuable upon exercise of outstanding options with a fixed exercise price. Pursuant to Rule 457(h) of the Securities Act, the aggregate offering price and the fee have been computed upon the basis of the price at which the option may be exercised, which was the closing price of a share of Common Stock on the date of grant of such option as reported on the Nasdaq Capital Market.

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300  
Raleigh, North Carolina 27607-7506

November 7, 2024

Avalo Therapeutics, Inc.  
540 Gaither Road, Suite 400  
Rockville, Maryland 20850

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 filed on or about the date hereof by Avalo Therapeutics, Inc., a Delaware corporation (the "Registrant"), with the Securities and Exchange Commission (the "Registration Statement") in connection with the registration under the Securities Act of 1933, as amended (the "Act"), of an aggregate of 384,000 shares of the Registrant's common stock, par value \$0.001 per share (the "Shares"). The Shares are issuable pursuant to the Registrant's Stock Option Agreements with certain employees, which were granted as inducements material to the individuals party thereto entering into employment with the Registrant (the "Inducement Grant Agreements"). In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the original of all documents submitted to us as copies thereof.

As the Registrant's legal counsel, we have examined the proceedings taken, and are familiar with the proceedings proposed to be taken, in connection with the sale of the Shares pursuant to the Inducement Grant Agreements.

It is our opinion that, upon completion of the proceedings being taken or contemplated by us, as the Registrant's counsel, to be taken prior to the issuance of the Shares, the Shares, when issued in the manner referred to in the Registration Statement and in accordance with the Inducement Grant Agreements, will be validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to the use of our name wherever appearing in the Registration Statement, including the Prospectus constituting a part thereof, and any amendments thereto.

This opinion letter is based as to matters of law solely on the General Corporation Law of the State of Delaware, as amended. We express no opinion herein as to any other statutes, rules or regulations.

Very truly yours,

/s/ WYRICK ROBBINS YATES & PONTON LLP



**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Non-Qualified Stock Option Inducement Awards of Avalo Therapeutics, Inc. of our report dated March 29, 2024, with respect to the consolidated financial statements of Avalo Therapeutics, Inc. and subsidiaries included in its Annual Report (Form 10-K) for the year ended December 31, 2023, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Tysons, Virginia  
November 7, 2024